Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Ltd (ADVENZYMES) last reported results for the quarter ended Jun 2026, with sales of ₹190 crore and net profit of ₹39 crore. The stock last traded at ₹278, a market capitalisation of ₹3,108 crore, on a P/E of 19.7. Over the past 52 weeks the stock has ranged between ₹252 and ₹420. Figures are as of 6 Oct 2026 and are not real time.
Advanced Enzyme Technologies Ltd share price and key metrics
- Current price
- ₹278
- Market cap
- ₹3,108 cr
- Stock P/E
- 19.7
- Book value
- ₹146
- ROE
- 10.2%
- ROCE
- 14.0%
- Dividend yield
- 1.92%
- 52w high / low
- 420/252
Metrics as of 6 Oct 2026. Not real time.
Track Advanced Enzyme Technologies Ltd
Cruxal reads every Advanced Enzyme Technologies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Advanced Enzyme Technologies Ltd growth and returns
- 10 Years
- 10%
- 5 Years
- 8%
- 3 Years
- 11%
- TTM
- 12%
- 10 Years
- 7%
- 5 Years
- 1%
- 3 Years
- 12%
- TTM
- 15%
- 10 Years
- -3%
- 5 Years
- -8%
- 3 Years
- -6%
- 1 Year
- -16%
- 10 Years
- 13%
- 5 Years
- 10%
- 3 Years
- 10%
- Last Year
- 10%
Advanced Enzyme Technologies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹190 cr, up 2.2% from ₹186 cr a year earlier. Net profit was ₹39 cr, down 2.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 146 | 169 | 167 | 186 | 185 | 172 | 203 | 190 |
| Expenses | 104 | 114 | 122 | 129 | 124 | 123 | 140 | 139 |
| Operating profit | 42 | 55 | 46 | 56 | 60 | 49 | 63 | 51 |
| OPM % | 29% | 33% | 27% | 30% | 33% | 29% | 31% | 27% |
| Other income | 10 | 8 | 9 | 9 | 10 | 20 | 7 | 13 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| Profit before tax | 42 | 53 | 43 | 55 | 60 | 58 | 60 | 54 |
| Tax % | 21% | 27% | 38% | 26% | 25% | 26% | 24% | 28% |
| Net profit | 33 | 39 | 27 | 40 | 45 | 43 | 45 | 39 |
| EPS (₹) | 2.94 | 3.37 | 2.37 | 3.57 | 3.87 | 3.80 | 3.84 | 3.31 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Advanced Enzyme Technologies Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 329 | 391 | 420 | 444 | 502 | 529 | 541 | 624 | 637 | 746 | 750 |
| Operating profit | 152 | 165 | 184 | 203 | 232 | 203 | 158 | 206 | 196 | 230 | 224 |
| OPM % | 46% | 42% | 44% | 46% | 46% | 38% | 29% | 33% | 31% | 31% | 30% |
| Net profit | 93 | 94 | 116 | 133 | 151 | 124 | 104 | 137 | 134 | 174 | 172 |
| EPS (₹) | 8.20 | 8.07 | 9.95 | 11.58 | 13.09 | 10.70 | 9.45 | 11.92 | 11.72 | 15.07 | 14.82 |
TTM is the trailing twelve months to the most recent quarter.
Advanced Enzyme Technologies Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | 442 | 537 | 657 | 817 | 948 | 1,066 | 1,213 | 1,302 | 1,398 | 1,610 |
| Borrowings | 54 | 67 | 35 | 28 | 23 | 35 | 34 | 47 | 39 | 32 |
| Other liabilities | 65 | 102 | 91 | 104 | 153 | 137 | 142 | 150 | 151 | 170 |
| Total liabilities | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
| Fixed assets | 421 | 491 | 495 | 563 | 601 | 619 | 649 | 650 | 679 | 692 |
| CWIP | 8 | 11 | 10 | 10 | 10 | 15 | 22 | 41 | 22 | 51 |
| Investments | 0 | 0 | 111 | 124 | 121 | 102 | 360 | 403 | 480 | 584 |
| Other assets | 153 | 226 | 188 | 275 | 413 | 524 | 380 | 427 | 430 | 507 |
| Total assets | 583 | 727 | 805 | 971 | 1,146 | 1,260 | 1,411 | 1,521 | 1,611 | 1,834 |
As reported by the company. Total assets equal total liabilities by construction.
Advanced Enzyme Technologies Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 107 | 116 | 129 | 141 | 163 | 122 | 140 | 141 | 142 | 157 |
| Cash from investing | -60 | -60 | -124 | -43 | -27 | 2 | -286 | -65 | -89 | -72 |
| Cash from financing | -65 | -2 | -43 | -39 | -26 | -48 | -26 | -59 | -73 | -70 |
| Net cash flow | -18 | 54 | -38 | 60 | 109 | 75 | -171 | 17 | -20 | 15 |
| Free cash flow | 97 | 105 | 116 | 90 | 143 | 95 | 102 | 94 | 108 | 105 |
| CFO / operating profit | 105% | 97% | 70% | 94% | 94% | 87% | 112% | 93% | 103% | 96% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Advanced Enzyme Technologies Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 31% | 25% | 24% | 22% | 22% | 16% | 12% | 15% | 13% | 14% |
| Debtor days | 55 | 55 | 51 | 61 | 63 | 61 | 68 | 58 | 66 | 71 |
| Inventory days | 352 | 339 | 363 | 361 | 346 | 402 | 343 | 375 | 378 | 335 |
| Days payable | 57 | 78 | 46 | 43 | 56 | 60 | 67 | 40 | 47 | 76 |
| Cash conversion cycle | 351 | 315 | 369 | 379 | 353 | 404 | 344 | 393 | 397 | 331 |
| Working capital days | 76 | 47 | 72 | 90 | 94 | 116 | 109 | 102 | 112 | 116 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Advanced Enzyme Technologies Ltd shareholding pattern
Promoters held 43.25% at Jun 2026, broadly unchanged since Jun 2025. FIIs 26.70% and DIIs 4.77%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.95% | 42.92% | 43.08% | 43.08% | 43.08% | 43.04% | 43.26% | 43.25% |
| FIIs | 12.63% | 12.57% | 11.90% | 23.45% | 25.41% | 25.85% | 25.50% | 26.70% |
| DIIs | 8.02% | 8.17% | 8.19% | 8.45% | 6.41% | 5.51% | 5.41% | 4.77% |
| Public | 36.40% | 36.31% | 36.82% | 25.00% | 25.09% | 25.62% | 25.85% | 25.28% |
| No. of shareholders | 66,758 | 67,351 | 65,322 | 67,589 | 69,637 | 68,051 | 66,193 | 63,599 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Advanced Enzyme Technologies Ltd corporate filings
- Advanced Enzyme Technologies Limited initiates buyback of 1.84 lakh equity shares at an average price of ₹269.02 per share, signaling capital return and potential positive market sentiment. Corp Actionhigh impact
Cruxal's analysis: Advanced Enzyme Technologies has bought back 1,84,148 equity shares (face value ₹2 each)…
Read the full analysis - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find enclosed herewith Certificate under Regulation 74(5) of the Securities and…
Read the full analysis - Advanced Enzyme Technologies Limited initiates buyback of 17,95,324 equity shares at an undisclosed average price, signaling potential capital management strategy Corp Actionhigh impact
Cruxal's analysis: Advanced Enzyme Technologies has announced a buyback of 17,95,324 fully paid-up equity…
Read the full analysis - Advanced Enzyme Technologies Buys Back 17.95 Lakh Shares at ₹272.37 on October 07, 2026, Indicating Shareholder Confidence Corp Actionhigh impact
Cruxal's analysis: Advanced Enzyme Technologies Limited executed a share buyback of 17,95,324 equity shares…
Read the full analysis - Advanced Enzyme Technologies Extinguishes 8.88 Lakh Shares Bought Back in September 2026, Confirmed by Regulatory FilingsCompany Updatehigh impact
Cruxal's analysis: Advanced Enzyme Technologies has completed the buyback of 8,88,296 equity shares at a…
Read the full analysis - Advanced Enzyme Technologies Limited initiates buyback of 17.69 lakh shares at ₹276.20 per share, signaling confidence in valuation Corp Actionhigh impact
Cruxal's analysis: Advanced Enzyme Technologies has announced a buyback of 17,69,324 equity shares…
Read the full analysis - Advanced Enzyme Technologies Limited initiates share buyback of 30,000 equity shares at an average price of ₹274.96 on October 5, 2026, cumulatively repurchasing 17.43 lakh shares since inception. Corp Actionmedium impact
Cruxal's analysis: Advanced Enzyme Technologies has conducted a buyback of 30,000 fully paid-up equity…
Read the full analysis - Advanced Enzyme Technologies Limited announces buyback of 17.13 lakh equity shares at an undisclosed average price, indicating ongoing capital return strategy amid stable operational performance Corp Actionhigh impact
Cruxal's analysis: Advanced Enzyme Technologies has repurchased 17.13 lakh fully paid-up equity shares of ₹…
Read the full analysis - Advanced Enzyme Technologies Limited initiates share buyback of 25,000 equity shares at an average price of ₹285.61 on September 30, 2026 Corp Actionhigh impact
Cruxal's analysis: Advanced Enzyme Technologies has announced a buyback of 25,000 fully paid-up equity…
Read the full analysis - Intimation of receipt of revised request from the Promoter Group Member requesting the reclassification from the Promoter Group Category to the Public Category of Shareholders of the Company ....Company Updatelow impact
- Daily Report pursuant to Regulation 18(i) of the Buyback Regulations regarding the Equity Shares bought back on September 29, 2026 Corp Actionmedium impact
- Advanced Enzyme Technologies Limited reports daily buyback of 25,000 equity shares at an average price of INR 288.41 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 25,000 equity shares…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed herewith the intimation regarding the closure of the Trading Window…
Read the full analysis - Advanced Enzyme Technologies Limited reports daily buyback of 50,000 equity shares at an average price of INR 295.80 Corp Actionmedium impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 50,000 equity shares…
Read the full analysis - Advanced Enzyme Technologies reports daily buyback of 64,668 shares at an average price of INR 298.03 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the daily progress of its ongoing open…
Read the full analysis - Advanced Enzyme Technologies Limited reports daily buyback of 63,616 equity shares at an average price of INR 297.47 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 63,616 equity shares…
Read the full analysis - Advanced Enzyme Technologies Limited reports daily share buyback of 1,136 equity shares Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the daily progress of its ongoing open…
Read the full analysis - Advanced Enzyme Technologies Limited reports daily buyback of 50,000 equity shares at an average price of INR 289.49 Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the purchase of 50,000 equity shares…
Read the full analysis - Advanced Enzyme Technologies Limited reports daily progress on open market share buyback Corp Actionlow impact
Cruxal's analysis: Advanced Enzyme Technologies Limited has disclosed the acquisition of 55,416 equity…
Read the full analysis - Advanced Enzyme Technologies receives revised promoter reclassification requestCompany Updatelow impact
Cruxal's analysis: Advanced Enzyme Technologies has received a revised request from certain promoter group…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.